ARCT Arcturus Therapeutics Holdings Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1768224 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-68.7%
TTM net income YoY-30.8%
TTM EPS YoY-26.0%
Revenue 3-yr CAGR-53.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-311.2%
Net margin-285.9%
FCF margin-204.7%
EBITDA margin-302.9%
Returns
ROE-44.4%
ROA-35.1%
ROIC (approx.)-533.8%
Asset turnover0.12x
Leverage & solvency
Liabilities / assets21.6%
Debt / equity0.00x
Current ratio6.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue-0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $82.03M | $152.31M | $166.80M | $206.00M | $12.36M |
| R&D expense | $112.21M | $195.16M | $192.13M | $147.75M | $173.76M |
| SG&A expense | $46.08M | $52.82M | $52.87M | $46.07M | $41.45M |
| Operating income | -$76.26M | -$95.67M | -$78.20M | $12.18M | -$202.85M |
| Pretax income | -$65.78M | -$80.94M | -$27.89M | $10.64M | -$203.67M |
| Income tax | — | -$4,000 | $1.83M | $1.29M | — |
| Net income | -$65.78M | -$80.94M | -$29.73M | $9.35M | -$203.67M |
| EBITDA | -$73.23M | -$92.12M | -$75.25M | $13.70M | -$201.66M |
| EPS (basic) | -2.40 | -3.00 | -1.12 | 0.35 | -7.74 |
| EPS (diluted) | -2.40 | -3.00 | -1.12 | 0.35 | -7.74 |
| Weighted avg. shares (diluted) | 27.39M | 27.00M | 26.63M | 27.09M | 26.32M |
| Balance sheet | |||||
| Cash & equivalents | $230.91M | $293.91M | $292.00M | $393.98M | $372.57M |
| Receivables | $5.56M | $3.97M | $32.06M | $2.76M | $3.37M |
| Current assets | $241.45M | $305.98M | $386.59M | $403.33M | $378.96M |
| PP&E, net | $6.74M | $9.53M | $12.43M | $12.41M | $5.64M |
| Total assets | $271.15M | $344.07M | $429.40M | $450.39M | $392.81M |
| Current liabilities | $36.38M | $65.49M | $81.99M | $126.98M | $99.54M |
| Short-term debt | — | — | — | $60.66M | $22.47M |
| Long-term debt | — | — | — | — | $40.63M |
| Total debt | — | — | — | — | $63.11M |
| Total liabilities | $57.16M | $103.09M | $150.89M | $180.07M | $164.60M |
| Shareholders' equity | $213.99M | $240.98M | $278.51M | $270.31M | $228.21M |
| Net debt | — | — | — | — | -$309.46M |
| Shares outstanding | 28.41M | 27.00M | 26.83M | 26.55M | 26.37M |
| Cash flow statement | |||||
| Operating cash flow | -$74.27M | -$59.75M | -$18.10M | $31.99M | -$135.04M |
| Capital expenditure | $230,000 | $648,000 | $2.90M | $7.73M | $3.41M |
| Free cash flow | -$74.50M | -$60.40M | -$21.00M | $24.27M | -$138.45M |
| Investing cash flow | -$230,000 | -$648,000 | -$2.90M | -$7.73M | -$3.41M |
| Financing cash flow | $13.38M | $5.42M | -$24.09M | -$2.86M | $48.02M |
| Depreciation & amortization | $3.02M | $3.54M | $2.96M | $1.53M | $1.19M |
| Stock-based compensation | $25.41M | $37.99M | $34.65M | $30.61M | $28.91M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.